Anbio Biotechnology [NNNN] vs Stevanato [STVN] Detailed Stock Comparison
Anbio Biotechnology
NASDAQ
Loading...
Stevanato
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Anbio Biotechnology wins in 6 metrics, Stevanato wins in 9 metrics, with 0 ties. Stevanato appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Anbio Biotechnology | Stevanato | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 713.33 | 47.40 | Stevanato |
| Price-to-Book Ratio | 105.16 | 4.84 | Stevanato |
| Debt-to-Equity Ratio | 0.00 | 27.86 | Anbio Biotechnology |
| PEG Ratio | N/A | 41.87 | N/A |
| EV/EBITDA | 793.57 | 28.90 | Stevanato |
| Profit Margin (TTM) | 28.99% | 11.16% | Anbio Biotechnology |
| Operating Margin (TTM) | -68.64% | 13.97% | Stevanato |
| EBITDA Margin (TTM) | N/A | 13.97% | N/A |
| Return on Equity | 14.83% | 9.14% | Anbio Biotechnology |
| Return on Assets (TTM) | 7.18% | 4.88% | Anbio Biotechnology |
| Free Cash Flow (TTM) | $2.08M | $-157.80M | Anbio Biotechnology |
| 1-Year Return | 641.77% | 30.77% | Anbio Biotechnology |
| Price-to-Sales Ratio (TTM) | 229.51 | 6.10 | Stevanato |
| Enterprise Value | $1.87B | $8.13B | Stevanato |
| EV/Revenue Ratio | 228.07 | 6.27 | Stevanato |
| Gross Profit Margin (TTM) | N/A | 27.24% | N/A |
| Revenue per Share (TTM) | $0 | $4 | Stevanato |
| Earnings per Share (Diluted) | $0.06 | $0.53 | Stevanato |
| Beta (Stock Volatility) | N/A | 0.56 | N/A |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Anbio Biotechnology vs Stevanato Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Anbio Biotechnology | -3.97% | -15.45% | 36.13% | 580.45% | 641.77% | 641.77% |
| Stevanato | 1.66% | -5.24% | 1.29% | 21.12% | 13.26% | 12.24% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Anbio Biotechnology | 641.77% | 641.77% | 641.77% | 641.77% | 641.77% | 641.77% |
| Stevanato | 30.77% | 37.49% | 27.71% | 27.71% | 27.71% | 27.71% |
Performance & Financial Health Analysis: Anbio Biotechnology vs Stevanato
| Metric | NNNN | STVN |
|---|---|---|
| Market Information | ||
| Market Cap | $1.88B | $6.86B |
| Market Cap Category | Small cap | Mid cap |
| 10 Day Avg. Volume | 126,990 | 420,151 |
| 90 Day Avg. Volume | 204,380 | 312,170 |
| Last Close | $42.80 | $25.12 |
| 52 Week Range | $5.18 - $55.65 | $17.12 - $28.00 |
| % from 52W High | -23.09% | -10.29% |
| All-Time High | $55.65 (Jul 15, 2025) | $36.30 (Aug 07, 2023) |
| % from All-Time High | -23.09% | -30.80% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.36% | 0.09% |
| Quarterly Earnings Growth | N/A | 0.41% |
| Financial Health | ||
| Profit Margin (TTM) | 0.29% | 0.11% |
| Operating Margin (TTM) | -0.69% | 0.14% |
| Return on Equity (TTM) | 0.15% | 0.09% |
| Debt to Equity (MRQ) | 0.00 | 27.86 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $0.41 | $5.19 |
| Cash per Share (MRQ) | $0.27 | $0.33 |
| Operating Cash Flow (TTM) | $2.08M | $212.40M |
| Levered Free Cash Flow (TTM) | $1.27M | $-130,964,617 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | $0.00 |
Valuation & Enterprise Metrics Analysis: Anbio Biotechnology vs Stevanato
| Metric | NNNN | STVN |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 713.33 | 47.40 |
| Forward P/E | N/A | 41.87 |
| PEG Ratio | N/A | 41.87 |
| Price to Sales (TTM) | 229.51 | 6.10 |
| Price to Book (MRQ) | 105.16 | 4.84 |
| Market Capitalization | ||
| Market Capitalization | $1.88B | $6.86B |
| Enterprise Value | $1.87B | $8.13B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 228.07 | 6.27 |
| Enterprise to EBITDA | 793.57 | 28.90 |
| Risk & Other Metrics | ||
| Beta | N/A | 0.56 |
| Book Value per Share (MRQ) | $0.41 | $5.19 |
Financial Statements Comparison: Anbio Biotechnology vs Stevanato
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | NNNN | STVN |
|---|---|---|
| Revenue/Sales | N/A | $256.60M |
| Cost of Goods Sold | N/A | $186.71M |
| Gross Profit | N/A | $69.89M |
| Research & Development | N/A | $5.93M |
| Operating Income (EBIT) | N/A | $34.63M |
| EBITDA | N/A | $55.55M |
| Pre-Tax Income | N/A | $35.11M |
| Income Tax | N/A | $8.60M |
| Net Income (Profit) | N/A | $26.51M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | NNNN | STVN |
|---|---|---|
| Cash & Equivalents | $11.76M | $90.72M |
| Total Current Assets | $18.53M | $845.47M |
| Total Current Liabilities | $1.73M | $463.26M |
| Long-Term Debt | N/A | $312.73M |
| Total Shareholders Equity | $17.19M | $1.42B |
| Retained Earnings | $17.17M | $890.85M |
| Property, Plant & Equipment | N/A | $110.62M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | NNNN | STVN |
|---|---|---|
| Operating Cash Flow | N/A | $100.69M |
| Capital Expenditures | N/A | $-69.33M |
| Free Cash Flow | N/A | $28.05M |
| Debt Repayment | N/A | $-55.75M |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | NNNN | STVN |
|---|---|---|
| Shares Short | 175,289 | 2.17M |
| Short Ratio | 0.74 | 7.35 |
| Short % of Float | 0.00% | 0.04% |
| Average Daily Volume (10 Day) | 126,990 | 420,151 |
| Average Daily Volume (90 Day) | 204,380 | 312,170 |
| Shares Outstanding | 43.89M | 272.90M |
| Float Shares | 39.69M | 48.81M |
| % Held by Insiders | 0.05% | 0.02% |
| % Held by Institutions | 0.05% | 1.13% |
Dividend Analysis & Yield Comparison: Anbio Biotechnology vs Stevanato
| Metric | NNNN | STVN |
|---|---|---|
| Last 12-Month Dividend | N/A | $0.00 |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | $0.04 |
| 3-Year Avg Dividend Yield | N/A | 0.26% |
| 3-Year Total Dividends | N/A | $0.12 |
| Ex-Dividend Date | N/A | Jun 04, 2024 |